Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterium tuberculosis metabolic and stress-response enzymes affected by pyrazinoic acid refers to a group of essential proteins targeted by the active form of the first-line antitubercular drug pyrazinamide (PZA). Pyrazinamide is a prodrug that is converted into pyrazinoic acid (POA) by the mycobacterial enzyme pyrazinamidase (PncA) [1.1.2]. Once activated, POA exerts its bactericidal and sterilizing effects by inhibiting multiple targets, most notably aspartate 1-decarboxylase (PanD), which is critical for coenzyme A (CoA) biosynthesis [1.2.1]. POA binding to PanD induces its degradation by the ClpC1-ClpP protease complex, leading to CoA depletion and metabolic failure [1.2.4, 1.2.5]. Other significant targets include ribosomal protein S1 (RpsA), which is involved in the ribosome-rescuing process of trans-translation, and Rv2783, a protein that regulates the stringent response by metabolizing ppGpp [1.1.2, 1.1.4]. These multi-target interactions, combined with the disruption of membrane energetics at acidic pH, allow PZA to effectively kill both actively growing and persistent mycobacteria within host lesions [1.3.3, 1.4.4]. Resistance is primarily mediated by mutations in the pncA gene, which prevents prodrug activation, or by mutations in the target genes themselves, such as panD and rpsA [1.2.2, 1.4.3].
Pyrazinamide is a prodrug converted by mycobacterial pyrazinamidase (PncA) into pyrazinoic acid (POA) [1.1.2, 1.3.4]. POA acts as a multi-target inhibitor: it binds to PanD and triggers its degradation via the ClpC1-ClpP protease complex (inhibiting CoA synthesis) [1.2.1, 1.2.4], binds to RpsA to inhibit trans-translation (ribosome rescue) [1.1.4, 1.2.2], and inhibits Rv2783 to disrupt the ppGpp-mediated stringent response [1.1.2, 1.3.1]. Additionally, POA disrupts the bacterial membrane potential and inhibits membrane transport, particularly under acidic conditions [1.3.3].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis metabolic and stress-response enzymes affected by pyrazinoic acid.